Edition:
United Kingdom

TapImmune Inc (TPIV.OQ)

TPIV.OQ on NASDAQ Stock Exchange Capital Market

3.13USD
5:46pm GMT
Change (% chg)

$-0.03 (-0.95%)
Prev Close
$3.16
Open
$3.11
Day's High
$3.13
Day's Low
$3.10
Volume
1,002
Avg. Vol
4,660
52-wk High
$5.35
52-wk Low
$2.62

Chart for

About

TapImmune Inc. is an immuno-oncology company. The Company specializes in the development of peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer. The Company is engaged in developing vaccines that target candidate breast cancers, colorectal cancers, ovarian cancers and non-small cell lung cancers.... (more)
No analyst recommendations are available for .

Overall

Beta: --
Market Cap(Mil.): --
Shares Outstanding(Mil.): 10.16
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Tapimmune Q3 loss earnings per share $0.39‍​

* Tapimmune provides third quarter 2017 corporate and clinical update

15 Nov 2017

BRIEF-TapImmune appoints Peter Hoang as president and CEO

* TapImmune appoints Peter Hoang as president and chief executive officer

25 Sep 2017

BRIEF-Tapimmune files for‍​ resale of 4.4 mln shares of common stock held by selling stockholders

* Tapimmune Inc - Files for‍​ resale 4.4 million shares of common stock which are currently held by selling stockholders - SEC filing Source text: [http://bit.ly/2hjwILz] Further company coverage:

20 Sep 2017

BRIEF-TapImmune reaches 50 pct patient enrollment benchmark in phase 2 study of novel t-cell vaccine targeting triple-negative breast cancer

* TapImmune reaches 50% patient enrollment benchmark in phase 2 study of novel t-cell vaccine targeting triple-negative breast cancer

27 Jun 2017

BRIEF-TapImmune to raise $6.82 million in a private placement

* Tapimmune inc. Enters into definitive agreements to raise $6.82 million in a private placement from accredited investors and from the exercise of warrants by existing institutional investors

22 Jun 2017

Earnings vs. Estimates

No consensus analysis data available.